Drug pricing initiatives during the Trump presidency
Tom Bulleit, Ropes & Gray health care partner, discusses the Trump Administration’s latest drug pricing initiatives.
Trending Similar Videos
Active nontransparent ETFs
Brian McCabe, Ropes & Gray asset management partner, discusses active nontransparent ETFs and the opportunities they offer to investors and asset managers of traditional mutual funds.
OECD's digital tax proposal
Kat Saunders Gregor, Ropes & Gray tax partner and co-founder of the firm’s tax controversy group, discusses the OECD’s digital tax proposal as well as actions being taken by several countries to pass digital services taxes of their own.
Section 101: confusion over patentable subject matter
Matt Rizzolo, Ropes & Gray IP litigation partner, addresses the ongoing confusion over what constitutes patentable subject matter under Section 101 of the Patent Act.
Matt Rizzolo, Ropes & Gray IP litigation partner, discusses the rise and impact of litigation finance, a rapidly growing third-party litigation funding model.
Trade secret litigation after the Defend Trade Secrets Act
Peter Brody, Ropes & Gray IP litigation partner, discusses the Defend Trade Secrets Act (DTSA) and how it has changed the trade secret litigation landscape since it was enacted in 2016.
Behavioral sciences approach to risk management
Amanda Raad, co-chair of Ropes & Gray’s anti-corruption & international risk practice, discusses the new data-driven behavioral sciences approach to risk management.